This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David S. Cross, MD; Jeffrey L. Platt, MD; Steven K. Juhn, MD; Fritz H. Bach, MD; George L. Adams, MD

Arch Otolaryngol Head Neck Surg. 1992;118(5):526-528.

Abstract
• Squamous cell carcinoma of the head and neck produces a prostaglandin, PGE₂, a potent inhibitor of cellular immune responses. We tested the effects of prostaglandin synthetase inhibition on the infiltration of squamous cell carcinoma of the head and neck with host lymphocytes. Tumor tissue samples were obtained from six patients (age range, 51 to 72 years) who presented with squamous cell carcinoma of the head and neck before and after 14 days of treatment with indomethacin (50 mg administered orally three times a day). Tumor-infiltrating immune cells were assayed in frozen tissue samples by indirect immunofluorescence. An eightfold increase in CD2⁺ lymphocytes compared with pretreatment tissue was observed. The number of CD4 and CD8 lymphocytes increased similiarly. CD57 lymphocytes increased 15-fold and CD11b cells increased 11-fold. No infiltrating B-cell populations were evident. Double-labeling studies revealed that the mononuclear cells were located outside blood vessel walls, indicating that they had infiltrated the tumor parenchyma. Our findings demonstrate that the administration of indomethacin is associated with the increased immune cell infiltration of squamous cell carcinoma of the head and neck. This suggests that inhibition of PGE₂ synthesis as it occurs in the tumor and or systemically may contribute to the homing of mononuclear cells to the tumor. These data suggest a mechanism to account for the clinical response to indomethacin previously reported in squamous cell carcinoma.

(Arch Otolaryngol Head Neck Surg. 1992;118:526-528)

Author Affiliations
From the Departments of Otolaryngology (Drs Cross, Juhn, and Adams), Pediatrics (Dr Platt), Cell Biology (Dr Platt), Neuroanatomy (Dr Platt), Laboratory Medicine and Pathology (Dr Bach), and Surgery (Dr Bach) and the Immunobiology Research Center (Drs Platt and Bach), University of Minnesota, Minneapolis.

Footnotes
Accepted for publication November 7, 1991.

Reprint requests to Department of Otolaryngology, University of Minnesota, Harvard at East River Road, UMHC Box 396, Minneapolis, MN 55455 (Dr Adams).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown and DuBois
JCO 2005;23:2840-2855.
ABSTRACT | FULL TEXT  

An Open Study to Assess the Efficacy and Safety of Topical 3% Diclofenac in a 2.5% Hyaluronic Acid Gel for the Treatment of Actinic Keratoses
Rivers and McLean
Arch Dermatol 1997;133:1239-1242.
ABSTRACT